Urologix Inc (ULGX) SEC Filing 10-Q Quarterly report for the period ending Tuesday, September 30, 2014

Urologix Inc

CIK: 882873 Ticker: ULGX




Urologix Reports First Quarter Fiscal Year 2015 Results


Recent Quarter Highlights


Reduced operating expenses 44% compared to the first quarter of the prior year.
Net loss reduced by 67% to $437,000 from a net loss of $1,334,000 in the first quarter of the prior year.


MINNEAPOLIS — November 4, 2014— Urologix®, Inc. (OTCQB: ULGX), the leading provider of in-office procedures for the safe, durable and effective treatment of BPH, today reported financial results for its fiscal year 2015 first quarter ended September 30, 2014.


First quarter revenue totaled $3.0 million, down 8% sequentially from the fourth quarter of fiscal year 2014 and down 20% compared to the first quarter of fiscal year 2014. Although the Company experienced a sequential revenue decline, first quarter fiscal year 2015 revenue met plan as the Company anticipated some decline in sales as a result of the April 2014 restructuring activities.


Total operating expense was $1.7 million for the first quarter of fiscal year 2015, a 44% reduction compared to $3.0 million of operating expense for the first quarter of fiscal year 2014. The decrease in operating expenses compared to the first quarter of fiscal year 2014 is a result of the strategic reorganization the Company implemented in the latter half of fiscal year 2014. Operating expenses for the fourth quarter of fiscal year 2014, excluding the $3.0 million non-cash goodwill impairment charge incurred during that quarter, were $2.0 million.


The Company reduced its net loss by 67% to a net loss of $437,000, or $0.02 per diluted share, for the first quarter of fiscal year 2015, when compared to a net loss of $1.3 million, or $0.06 per diluted share, in the first quarter of fiscal year 2014.


“We are pleased with the first quarter of fiscal year 2015 results for both revenue achievement and expense management. We expected some lower sales volume in this new fiscal year with our new sales deployment model and organizational structure, but believe the restructuring has allowed us to focus on a stronger base of business to first stabilize and then begin to expand upon,” stated Greg Fluet, Chief Executive Officer. “Our primary goals are to end fiscal year 2015 with positive cash flow from operations and support building upon the evidence demonstrating the cost-effectiveness of our in-office BPH technologies. Achieving these goals should build strategic value for our shareholders and creditors.”




As of September 30, 2014, the Company’s cash balance was $545,000 compared to $718,000 as of June 30, 2014, resulting in cash utilization of $173,000. The first quarter cash utilization declined $566,000 compared to the first quarter of the prior year when we utilized $739,000 of cash. The first quarter of the fiscal year typically has higher cash spend of any quarter in the year as we pay for several annual expenses such as our annual insurance premiums. In the first quarter of fiscal year 2015 payments for our annual insurance premiums alone totaled $254,000, more than our total cash utilization in the quarter. Of the Company’s $739,000 of cash utilization in the prior year first quarter, $267,000 was payments for prior year insurance premiums.


The Company’s cash needs will be determined by a number of items including its operating performance and the timing of payment of annual royalties for Prostiva due and unpaid. Royalty payments and other fees due and unpaid to Medtronic totaled $780,000 as of September 30, 2014. An additional $650,000 of annual royalty payments became due to Medtronic in October 2014. All of the currently due and unpaid royalty amounts are included in short term deferred acquisition payments under current liabilities as of September 30, 2014.


Regarding the amounts due and unpaid to Medtronic, “Urologix and Medtronic both share a sincere commitment to patients and urologists. We recognize Medtronic’s continuing rights under the agreements, and are working with Medtronic in our effort to build the business collaboratively through Medtronic’s engagement as an observer on our Board of Directors” said Mr. Fluet.


The gross margin rate has remained consistent, with gross profit for the first quarter of fiscal year 2015 of $1.5 million, or 48% of revenue, compared to $1.9 million, or 49% of revenue, in the first quarter of fiscal year 2014, and $1.6 million, or 48% of revenue, in the fourth quarter of fiscal year 2014.



Earnings Call Information


Urologix will host a conference call with the financial community to discuss fiscal year 2015 first quarter results on Tuesday, November 4, 2014 at 4:00 p.m. Central Time. To listen to the call, please dial 1-866-318-8617 and enter the Participant Passcode 57661939 at least 10 minutes prior to the call. A live webcast of the call will be available through the investor relations section of the Company’s website at and available for replay approximately two hours after the completion of the call.



About Urologix


Urologix, Inc., based in Minneapolis, develops, manufactures, markets and distributes minimally invasive medical products for the treatment of obstruction and symptoms due to Benign Prostatic Hyperplasia (BPH). Urologix’ Cooled ThermoTherapy™ produces targeted microwave energy combined with a unique cooling mechanism to protect healthy tissue and enhance patient comfort. The Prostiva® RF Therapy System delivers radio frequency energy directly into the prostate destroying prostate tissue, reducing constriction of the urethra, and thereby relieving BPH symptoms. Both of these therapies provide safe, effective and lasting relief of the symptoms and obstruction due to BPH. Prostiva® is a registered trademark of Medtronic, Inc., used under license. All other trademarks are the property of Urologix.




If you’d like more information on this topic, please contact Greg Fluet at (763) 475-1400 or or to learn more about Urologix and its products and services, visit their website at


The Urologix, Inc. logo is available at


Forward Looking Statements


This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, words such as “may,” “will,” “expect,” “believe,” “anticipate,” “estimate” or “continue” or comparable terminology are intended to identify forward-looking statements. Such forward looking statements include, for example, the effectiveness of the Company’s sales and marketing strategies and the impact of the Company’s strategic restructurings, the Company’s future revenue and operating performance, or about the development and marketing of products. The statements made by the Company are based upon management’s current expectations and are subject to certain risks and uncertainties that could cause the actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include market conditions and other factors beyond the Company’s control and the risk factors and other cautionary statements described in the Company’s Annual Report on Form 10-K for the year ended June 30, 2014 and other documents filed with the Securities and Exchange Commission.


Urologix Media Contact Urologix Investor Relations Contact
Susan Overby Greg Fluet
(763) 745-1540 (763) 475-1400








Urologix, Inc.

Statements of Operations

(Unaudited, in thousands, except per share data)


   Three Months Ended
September 30,
   2014   2013 
Sales  $3,021   $3,779 
Cost of goods sold   1,559    1,915 
Gross profit   1,462    1,864 
Costs and expenses:          
Sales and marketing   810    1,845 
General and administrative   488    685 
Research and development   334    421 
Change in value of acquisition consideration       (9)
Medical device tax   48    61 
Amortization   23    23 
Total costs and expenses   1,703    3,026 
Operating loss   (241)   (1,162)
Interest expense   (188)   (161)
Foreign currency exchange gain/(loss)   (3)   1 
Loss before income taxes   (432)   (1,322)
Income tax expense   5    12 
Net loss  $(437)  $(1,334)
Net loss per common share—basic and diluted  $(0.02)  $(0.06)
Weighted average number of common shares outstanding—basic and diluted   21,487    21,020 













Urologix, Inc.

Balance Sheets

(in thousands)


   September 30,
   June 30,
   (unaudited)   (audited) 
Current assets:          
Cash  $545   $718 
Accounts receivable, net   1,526    1,502 
Inventories   1,314    1,397 
Prepaids and other current assets   284    63 
Total current assets   3,669    3,680 
Property and equipment:          
Property and equipment   12,166    12,162 
Less accumulated depreciation   (11,769)   (11,691)
Property and equipment, net   397    471 
Other intangible assets, net   1,316    1,370 
Long-term inventories   131    141 
Other assets   5    5 
Total assets  $5,518   $5,667 
Current liabilities:          
Accounts payable  $929   $892 
Accrued compensation   477    487 
Short-term deferred acquisition payment   1,375    1,339 
Current portion of long-term debt   747    747 
Interest payable   406    322 
Other accrued expenses   539    505 
Total current liabilities   4,473    4,292 
Long-term deferred acquisition payment   3,831    3,730 
Long-term debt   4,586    4,586 
Other accrued liabilities   27    36 
Total liabilities   12,917    12,644 
Shareholders’ deficit:          
Common stock   211    209 
Additional paid-in capital   119,453    119,440 
Accumulated deficit   (127,063)   (126,626)
Total shareholders’ deficit   (7,399)   (6,977)
Total liabilities and shareholders’ deficit  $5,518   $5,667 





Urologix, Inc.

Condensed Statements of Cash Flows

(Unaudited, in thousands)


   Three-Months Ended
September 30,
   2014   2013 
Operating Activities:          
Net loss  $(437)  $(1,334)
Adjustments to reconcile net loss to net cash used in operating activities:          
Depreciation and amortization   134    157 
Employee stock-based compensation expense   15    68 
Provision for bad debts   15    (19)
Accretion expense on deferred acquisition payments   137    110 
Net adjustment to acquisition consideration       (9)
Deferred income taxes       7 
Change in operating items:          
Accounts receivable   (39)   30 
Inventories   90    (15)
Prepaids and other assets   (221)   (260)
Accounts payable   37    485 
Accrued expenses and deferred income   15    (38)
Interest payable   84    84 
Net cash used in operating activities   (170)   (734)
Investing Activities:          
Purchases of property and equipment   (1)   (2)
Purchases of intellectual property   (2)   (3)
Net cash used for investing activities   (3)   (5)
Net decrease in cash   (173)   (739)
Beginning of period   718    2,290 
End of period  $545   $1,551 







The following information was filed by Urologix Inc (ULGX) on Wednesday, November 5, 2014 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one quarter to another to evaluate Urologix Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Urologix Inc.


Assess how Urologix Inc's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Urologix Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2014 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 10-Q Quarterly Report

Document And Entity Information
Condensed Balance Sheets
Condensed Balance Sheets (parenthetical)
Condensed Statements Of Cash Flows
Condensed Statements Of Operations
Basic And Diluted Loss Per Share
Basic And Diluted Loss Per Share (details)
Basis Of Presentation
Commitments And Contingencies
Fair Value Measurements
Fair Value Measurements (narrative) (details)
Fair Value Measurements (reconciliation Of Contingent Consideration Liability) (details)
Fair Value Measurements (tables)
Financing Arrangements
Financing Arrangements (details)
Income Taxes
Income Taxes (narrative) (details)
Intangible Assets
Intangible Assets (future Amortization Expense Related To Net Carrying Amount Of Intangible Assets) (details)
Intangible Assets (narrative) (details)
Intangible Assets (schedule Of Intangible Assets) (details)
Intangible Assets (tables)
Inventories (narrative) (details)
Inventories (schedule Of Inventories) (details)
Inventories (tables)
Liquidity (details)
Recently Issued Accounting Pronouncements
Stock-based Compensation
Stock-based Compensation (amounts Recognized In Financial Statements Related To Stock-based Compensation) (details)
Stock-based Compensation (assumptions Used To Estimate Fair Value Of Options Granted) (details)
Stock-based Compensation (narrative) (details)
Stock-based Compensation (summary Of Non-vested Restricted Stock Activity) (details)
Stock-based Compensation (summary Of Stock Option Activity) (details)
Stock-based Compensation (tables)
Use Of Estimates
Warranty (details)
Warranty (tables)
Ticker: ULGX
CIK: 882873
Form Type: 10-Q Quarterly Report
Accession Number: 0000897101-14-001658
Submitted to the SEC: Thu Nov 13 2014 2:31:39 PM EST
Accepted by the SEC: Thu Nov 13 2014
Period: Tuesday, September 30, 2014
Industry: Electromedical And Electrotherapeutic Apparatus

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: